患者报告的结果:比较肺癌的功能性回避和标准胸部放射治疗。

IF 3.3 Q2 ONCOLOGY
JCO Clinical Cancer Informatics Pub Date : 2025-02-01 Epub Date: 2025-02-04 DOI:10.1200/CCI-24-00202
Spencer J Poiset, Joseph Lombardo, Edward Castillo, Richard Castillo, Bernard Jones, Moyed Miften, Brian Kavanagh, Adam P Dicker, Cullen Boyle, Nicole L Simone, Benjamin Movsas, Inga Grills, Chad G Rusthoven, Yevgeniy Vinogradskiy, Lydia Wilson
{"title":"患者报告的结果:比较肺癌的功能性回避和标准胸部放射治疗。","authors":"Spencer J Poiset, Joseph Lombardo, Edward Castillo, Richard Castillo, Bernard Jones, Moyed Miften, Brian Kavanagh, Adam P Dicker, Cullen Boyle, Nicole L Simone, Benjamin Movsas, Inga Grills, Chad G Rusthoven, Yevgeniy Vinogradskiy, Lydia Wilson","doi":"10.1200/CCI-24-00202","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Novel methods generate functional images using image processing techniques combined with four-dimensional computed tomography (4DCT) data (4DCT-ventilation). 4DCT-ventilation was implemented in a phase II, multicenter functional avoidance clinical trial. The work compares functional avoidance patient-reported outcomes (PROs) against historical standards.</p><p><strong>Methods: </strong>Patients with locally advanced lung cancer undergoing curative-intent chemoradiation were accrued. 4DCT-ventilation imaging was generated and functional avoidance treatment plans created reduced dose to functional lung. PRO instruments included Functional Assessment of Cancer Therapy Lung questionnaire and accompanying subscales (including the Trial Outcome Index [TOI]), EuroQol-5 Dimension (EQ-5D), and EQ-Visual Analog Scale (EQ-VAS). The average change from baseline and percentage of clinically meaningful declines were calculated. We compared results against PROs from RTOG 0617 and PACIFIC trial data using Student t-tests and chi-square tests.</p><p><strong>Results: </strong>Fifty-nine patients completed baseline PRO surveys. The median age was 65 (44-86) years, non-small cell lung cancer comprised 83%, and median dose was 60 Gy in 30 fractions. The percent of patients with clinically meaningful decline in FACT-TOI at 12 months was 47.8% for RTOG 0617% and 26.8% for functional avoidance (<i>P</i> = .03). The functional avoidance cohort demonstrated a significantly (<i>P</i> = .012) higher change in EQ-VAS score at 12 months (9.9 ± 3.3; average ± SE) compared with the PACIFIC cohort (1.6 ± 0.6).</p><p><strong>Conclusion: </strong>The current work demonstrates improved PROs from a phase II functional avoidance trial in certain subscales (FACT-TOI and EQ-VAS) compared with PROs from seminal studies (RTOG 0617 and PACIFIC). The presented data support investigation of 4DCT functional avoidance in a phase III setting.</p>","PeriodicalId":51626,"journal":{"name":"JCO Clinical Cancer Informatics","volume":"9 ","pages":"e2400202"},"PeriodicalIF":3.3000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11801246/pdf/","citationCount":"0","resultStr":"{\"title\":\"Patient-Reported Outcomes: Comparing Functional Avoidance and Standard Thoracic Radiation Therapy in Lung Cancer.\",\"authors\":\"Spencer J Poiset, Joseph Lombardo, Edward Castillo, Richard Castillo, Bernard Jones, Moyed Miften, Brian Kavanagh, Adam P Dicker, Cullen Boyle, Nicole L Simone, Benjamin Movsas, Inga Grills, Chad G Rusthoven, Yevgeniy Vinogradskiy, Lydia Wilson\",\"doi\":\"10.1200/CCI-24-00202\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Novel methods generate functional images using image processing techniques combined with four-dimensional computed tomography (4DCT) data (4DCT-ventilation). 4DCT-ventilation was implemented in a phase II, multicenter functional avoidance clinical trial. The work compares functional avoidance patient-reported outcomes (PROs) against historical standards.</p><p><strong>Methods: </strong>Patients with locally advanced lung cancer undergoing curative-intent chemoradiation were accrued. 4DCT-ventilation imaging was generated and functional avoidance treatment plans created reduced dose to functional lung. PRO instruments included Functional Assessment of Cancer Therapy Lung questionnaire and accompanying subscales (including the Trial Outcome Index [TOI]), EuroQol-5 Dimension (EQ-5D), and EQ-Visual Analog Scale (EQ-VAS). The average change from baseline and percentage of clinically meaningful declines were calculated. We compared results against PROs from RTOG 0617 and PACIFIC trial data using Student t-tests and chi-square tests.</p><p><strong>Results: </strong>Fifty-nine patients completed baseline PRO surveys. The median age was 65 (44-86) years, non-small cell lung cancer comprised 83%, and median dose was 60 Gy in 30 fractions. The percent of patients with clinically meaningful decline in FACT-TOI at 12 months was 47.8% for RTOG 0617% and 26.8% for functional avoidance (<i>P</i> = .03). The functional avoidance cohort demonstrated a significantly (<i>P</i> = .012) higher change in EQ-VAS score at 12 months (9.9 ± 3.3; average ± SE) compared with the PACIFIC cohort (1.6 ± 0.6).</p><p><strong>Conclusion: </strong>The current work demonstrates improved PROs from a phase II functional avoidance trial in certain subscales (FACT-TOI and EQ-VAS) compared with PROs from seminal studies (RTOG 0617 and PACIFIC). The presented data support investigation of 4DCT functional avoidance in a phase III setting.</p>\",\"PeriodicalId\":51626,\"journal\":{\"name\":\"JCO Clinical Cancer Informatics\",\"volume\":\"9 \",\"pages\":\"e2400202\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11801246/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JCO Clinical Cancer Informatics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1200/CCI-24-00202\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/4 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO Clinical Cancer Informatics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1200/CCI-24-00202","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/4 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:利用图像处理技术结合四维计算机断层扫描(4DCT)数据(4DCT-通气)生成功能图像的新方法。在一项II期多中心功能回避临床试验中实施了dct -通气。该研究将功能性回避患者报告的结果(PROs)与历史标准进行了比较。方法:对局部晚期肺癌患者进行治疗性放化疗。生成dct -通气成像,功能回避治疗方案对功能肺产生减少剂量。PRO工具包括肺癌治疗功能评估问卷及其附属量表(包括试验结果指数[TOI])、EuroQol-5维度(EQ-5D)和eq -视觉模拟量表(EQ-VAS)。计算从基线的平均变化和临床意义下降的百分比。我们使用学生t检验和卡方检验将结果与RTOG 0617和PACIFIC试验数据的PROs进行比较。结果:59例患者完成了基线PRO调查。中位年龄为65(44-86)岁,非小细胞肺癌占83%,中位剂量为60 Gy,分为30组。12个月时临床有意义的FACT-TOI下降的患者比例为:RTOG为47.8%,RTOG为0617%,功能性回避为26.8% (P = 0.03)。功能回避组在12个月时EQ-VAS评分的变化显著(P = 0.012)(9.9±3.3;平均±SE),而太平洋队列(1.6±0.6)。结论:目前的工作表明,与开创性研究(RTOG 0617和PACIFIC)的PROs相比,II期功能性回避试验在某些子量表(FACT-TOI和EQ-VAS)中的PROs有所改善。提出的数据支持在III期设置4DCT功能回避的调查。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Patient-Reported Outcomes: Comparing Functional Avoidance and Standard Thoracic Radiation Therapy in Lung Cancer.

Purpose: Novel methods generate functional images using image processing techniques combined with four-dimensional computed tomography (4DCT) data (4DCT-ventilation). 4DCT-ventilation was implemented in a phase II, multicenter functional avoidance clinical trial. The work compares functional avoidance patient-reported outcomes (PROs) against historical standards.

Methods: Patients with locally advanced lung cancer undergoing curative-intent chemoradiation were accrued. 4DCT-ventilation imaging was generated and functional avoidance treatment plans created reduced dose to functional lung. PRO instruments included Functional Assessment of Cancer Therapy Lung questionnaire and accompanying subscales (including the Trial Outcome Index [TOI]), EuroQol-5 Dimension (EQ-5D), and EQ-Visual Analog Scale (EQ-VAS). The average change from baseline and percentage of clinically meaningful declines were calculated. We compared results against PROs from RTOG 0617 and PACIFIC trial data using Student t-tests and chi-square tests.

Results: Fifty-nine patients completed baseline PRO surveys. The median age was 65 (44-86) years, non-small cell lung cancer comprised 83%, and median dose was 60 Gy in 30 fractions. The percent of patients with clinically meaningful decline in FACT-TOI at 12 months was 47.8% for RTOG 0617% and 26.8% for functional avoidance (P = .03). The functional avoidance cohort demonstrated a significantly (P = .012) higher change in EQ-VAS score at 12 months (9.9 ± 3.3; average ± SE) compared with the PACIFIC cohort (1.6 ± 0.6).

Conclusion: The current work demonstrates improved PROs from a phase II functional avoidance trial in certain subscales (FACT-TOI and EQ-VAS) compared with PROs from seminal studies (RTOG 0617 and PACIFIC). The presented data support investigation of 4DCT functional avoidance in a phase III setting.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.20
自引率
4.80%
发文量
190
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信